Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 01, 2021 / 09:00PM GMT
Release Date Price: €69.84 (+5.28%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Hi, everyone. Welcome to the Cowen Healthcare Conference 2021 Fireside Chat with Sage. With us today from Sage is the new CEO, Barry Greene. Barry, thank you for -- thank you for joining us today.

Questions & Answers

Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

I'm going to -- I'm just going to kick it off with a strategy question, and you can take this opportunity to elaborate a little bit if you want, if you think that there's something not covered in our discussion outline, but I'm sure you've gotten this question a number of times for the last couple of months.

Why Sage? I mean I've heard from third parties that your phone was ringing off the hook the second, your your planned move from Alnylam was announced. So what did you see in this opportunity, not just as a Board member, which was the original plan, but in the CEO role. What withdrew to Sage at a time where it was

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot